Psoriasis and IBD share pathogenetic pathways such as the IL-23/IL-17 pathway, have common genetic risk alleles and are associated with abnormalities in intestinal and skin microflora and both respond to anti-TNF and anti-p40 treatment (121). The gene discussed is IL17A; the disease is inflammatory bowel disease.